IntelGenx Technologies Corp (IGXT)

[Tasso9]

Posted: Wednesday, November 15, 2017 9:45 AM
Joined: 12/12/2011
Posts: 4075


These are important points, Serenoa and larrytherunner. Montelukast/Singulair target a particular g protein-coupled receptor (cysteinyl leukotriene receptor) that is involved in asthma, inflammation, and Alzheimer's disease.

https://www.ncbi.nlm.nih.gov/pubmed/24456746

There are many other g protein-coupled receptors involved in Alzheimer's disease plus in some cases receptor tyrosine kinases. So maybe the question is does Montelukast do more that inhibit one form of g protein-coupled receptor or does it have an additional mechanism of action (as an antioxidant, for instance). If it does then it may provide an effective treatment for many people during the early stages of Alzheimer's disease.


Back to top
baystate
Posted: Friday, December 8, 2017 12:01 PM
Joined: 1/25/2017
Posts: 2


Intelgenx does now have the funds to start Montelukast/dementia study in first quarter of 2018...they trade on stock exchange=IGXT symbol
Back to top
Larrytherunner
Posted: Friday, December 8, 2017 2:30 PM
Joined: 2/26/2016
Posts: 71


Baystate, thanks for the information. I had read in November that Intelgenx had reached an agreement with the Canadian government for clinical trials. I think when the results come out that this drug is the first effective treatment for Alzheimer's, the big pharmaceutical company people are going to be shocked that, with all the billions they spent on new drug research searching for a high priced blockbuster, they were beaten by an inexpensive drug that has been available to the public for more than 15 years.

I have been taking this drug now for more than 22 months and have gone from extreme mental fatigue and occasional confusion to feeling completely normal again. I am thankful that there are investors like you that will give many other people a chance to resume leading a normal life. I hope you get a big return on your investment.